LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraine

Photo by franganillo from unsplash

ABSTRACT Introduction Refractory migraine is associated with low quality of life and great socioeconomic burden. Despite high need for effective, tolerable preventive therapies, there has been little research on potential… Click to show full abstract

ABSTRACT Introduction Refractory migraine is associated with low quality of life and great socioeconomic burden. Despite high need for effective, tolerable preventive therapies, there has been little research on potential therapeutic options. Monoclonal antibodies (mAbs) against Calcitonin Gene-Related Peptide (CGRP) are the first preventive therapeutic approach for migraine based on the underlying pathophysiology. Areas covered Following a brief introduction into the term ‘refractory migraine,’ the authors reviewavailable treatment options, focusing on current phase III trials of substances acting on the CGRP pathway. Expert opinion No uniform definition for refractory migraine is available. The vast majority of proposals recommend treatment failure of 2–4 drug classes as a key diagnostic criterion. Phase III studies on CGRP-(receptor) mAbs demonstrated excellent efficacy and tolerability in patients with chronic and episodic migraine including subjects with multiple unsuccessful conventional therapy attempts. However, more comparator trials showing superiority of mAbs versus oral preventatives, such as the HER-MEs study are needed. In summary, with the CGRP antibodies, a group of drugs has entered the market which will most likely not only significantly improve the quality of life of many individual migraine patients but could also reduce indirect health-care costs associated with migraine by reducing recurrent medical consultations.

Keywords: migraine; pharmacotherapy prophylactic; refractory migraine; treatment; advances pharmacotherapy

Journal Title: Expert Opinion on Pharmacotherapy
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.